N-(3-(benzyloxy)pyridin-2-yl)benzenesulfonamide | 877459-36-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-(benzyloxy)pyridin-2-yl)benzenesulfonamide
• 英文别名: N-[3-(benzyloxy)pyridin-2-yl]benzenesulfonamide；N-(3-phenylmethoxypyridin-2-yl)benzenesulfonamide
• CAS: 877459-36-4
• 化学式: C₁₈H₁₆N₂O₃S
• 分子量: 340.403
• InChiKey: JBHHMMLJGNLVNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  76.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-氨基-3-苄氧基吡啶 、 苯磺酰氯 以 四氢呋喃 为溶剂， 反应 40.0h， 以30%的产率得到N-(3-(benzyloxy)pyridin-2-yl)benzenesulfonamide
  参考文献：
  名称：

  Structure-Based Design, Synthesis, and Biological Evaluation of Novel Inhibitors of Human Cyclophilin A

  摘要：

  Cyclophilin A is involved in many cellular processes, including protein folding and intracellular transports. Because cyclophilin A has been shown to interact with HIV-1 gag proteins and to enhance the viral infectivity, nonimmunosuppressive cyclophilin A ligands may represent a new class of therapeutic agents against HIV. Here, we report a virtual screening using structure- and pharmacophore-based design to identify original nonpeptidic cyclophilin ligands. Following a lead identification of compounds 1 [1-(3-benzyloxypyridin-2-yl)-3-(3-chlorophenyl)urea] and 2 [1-(3-benzyloxypyridin-2-yl)-3-(3-trifluoromethylphenyl)urea] (IC50 = 0.3 mu M), a series of molecules were synthesized from a diarylurea scaffold and evaluated for their in vitro ability to inhibit the cis-trans isomerase activity of cyclophilin A. Molecular modifications provided several more potent compounds, in particular analogues 4d and 4i with IC50 of 14 and 20 nM, respectively. Then, we evaluated the effect of analogues 1 and 2 on HIV virion infectivity in both immortalized and primary cells. Both 1 and 2 reduced virion infectivity in the replication-defective one-round infection assay, but only 1 impaired wild-type HIV infection in human peripheral blood mononuclear cells.

  DOI：

  10.1021/jm050716a

文献信息

• AQUAPORIN 4 FUNCTION PROMOTER AND PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS
  申请人：Niigata University

  公开号：EP3424502A1

  公开（公告）日：2019-01-09

  An aquaporin 4 function promotor contains a compound represented by Formula (1) or (2) or a pharmaceutically acceptable salt thereof, as an active ingredient.         NH2C(NH)NH(CH2)n11SO3H     (1) (In the formula, n11 represents an integer of 1 to 10, and R21 represents one selected from the group consisting of an alkyl group having 1 to 10 carbon atoms, an alicyclic heterocyclic group, an aromatic hydrocarbon group, and an aromatic heterocyclic group.)

  一种水蒸气素 4 功能促进剂含有由式（1）或（2）代表的化合物或其药学上可接受的盐作为活性成分。 NH2C(NH)NH(CH2)n11SO3H (1) (式中，n11 代表 1 至 10 的整数，R21 代表选自由 1 至 10 个碳原子的烷基、脂环杂环基团、芳香烃基团和芳香杂环基团组成的组)。
• Aquaporin 4 function promotor and pharmaceutical composition for neurological disorders
  申请人：NIIGATA UNIVERSITY

  公开号：US10632084B2

  公开（公告）日：2020-04-28

  An aquaporin 4 function promotor contains a compound represented by Formula (1) or (2) or a pharmaceutically acceptable salt thereof, as an active ingredient. (In the formula, n11 represents an integer of 1 to 10, and R21 represents one selected from the group consisting of an alkyl group having 1 to 10 carbon atoms, an alicyclic heterocyclic group, an aromatic hydrocarbon group, and an aromatic heterocyclic group.)

  一种水蒸气素 4 功能促进剂含有由式（1）或（2）代表的化合物或其药学上可接受的盐作为活性成分。 (式中，n11 代表 1 至 10 的整数，R21 代表选自由 1 至 10 个碳原子的烷基、脂环杂环基团、芳香烃基团和芳香杂环基团组成的组)。
• AQUAPORIN 4 FUNCTION PROMOTOR AND PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS
  申请人：NIIGATA UNIVERSITY

  公开号：US20190091182A1

  公开（公告）日：2019-03-28

  An aquaporin 4 function promotor contains a compound represented by Formula (1) or (2) or a pharmaceutically acceptable salt thereof, as an active ingredient. (In the formula, n 11 represents an integer of 1 to 10, and R 21 represents one selected from the group consisting of an alkyl group having 1 to 10 carbon atoms, an alicyclic heterocyclic group, an aromatic hydrocarbon group, and an aromatic heterocyclic group.)
• [EN] DRUG FOR PREVENTING OR TREATING HYDROCEPHALUS AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HYDROCEPHALUS<br/>[FR] MÉDICAMENT POUR LA PRÉVENTION OU LE TRAITEMENT D'UNE HYDROCÉPHALIE ET COMPOSITION PHARMACEUTIQUE POUR LA PRÉVENTION OU LE TRAITEMENT D'UNE HYDROCÉPHALIE<br/>[JA] 水頭症の予防又は治療薬及び水頭症の予防又は治療用医薬組成物
  申请人：UNIV NIIGATA

  公开号：WO2021111946A1

  公开（公告）日：2021-06-10

  水頭症の予防又は治療薬は、下記一般式（１）で表される化合物、又はその薬学的に許容できる塩を有効成分として含有する。 （式中、Ｒは炭素数１以上１０以下の置換基を有してもよい飽和脂肪族炭化水素基、脂環式複素環基、芳香族炭化水素基、又は芳香族複素環基である。）